
Arshad M. Khanani, MD, MA, FASRS
Advertisement
Articles by Arshad M. Khanani, MD, MA, FASRS


Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.

Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.

OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.
Advertisement
Latest Updated Articles
- OPT-302 VEGF-C/D “trap” molecule for AMD promising in Phase 2b, moves to Phase 3
Published: November 7th 2022 | Updated:
Advertisement
Advertisement
Trending on Modern Retina
1
Current and Emerging Treatments for Geographic Atrophy and When to Initiate Therapy
2
AAO 2025: Subretinal drusenoid deposits in Black and Hispanic patients with AMD
3
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
4